À propos de la propriété intellectuelle Formation en propriété intellectuelle Respect de la propriété intellectuelle Sensibilisation à la propriété intellectuelle La propriété intellectuelle pour… Propriété intellectuelle et… Propriété intellectuelle et… Information relative aux brevets et à la technologie Information en matière de marques Information en matière de dessins et modèles industriels Information en matière d’indications géographiques Information en matière de protection des obtentions végétales (UPOV) Lois, traités et jugements dans le domaine de la propriété intellectuelle Ressources relatives à la propriété intellectuelle Rapports sur la propriété intellectuelle Protection des brevets Protection des marques Protection des dessins et modèles industriels Protection des indications géographiques Protection des obtentions végétales (UPOV) Règlement extrajudiciaire des litiges Solutions opérationnelles à l’intention des offices de propriété intellectuelle Paiement de services de propriété intellectuelle Décisions et négociations Coopération en matière de développement Appui à l’innovation Partenariats public-privé Outils et services en matière d’intelligence artificielle L’Organisation Travailler avec nous Responsabilité Brevets Marques Dessins et modèles industriels Indications géographiques Droit d’auteur Secrets d’affaires Académie de l’OMPI Ateliers et séminaires Application des droits de propriété intellectuelle WIPO ALERT Sensibilisation Journée mondiale de la propriété intellectuelle Magazine de l’OMPI Études de cas et exemples de réussite Actualités dans le domaine de la propriété intellectuelle Prix de l’OMPI Entreprises Universités Peuples autochtones Instances judiciaires Ressources génétiques, savoirs traditionnels et expressions culturelles traditionnelles Économie Financement Actifs incorporels Égalité des genres Santé mondiale Changement climatique Politique en matière de concurrence Objectifs de développement durable Technologies de pointe Applications mobiles Sport Tourisme PATENTSCOPE Analyse de brevets Classification internationale des brevets Programme ARDI – Recherche pour l’innovation Programme ASPI – Information spécialisée en matière de brevets Base de données mondiale sur les marques Madrid Monitor Base de données Article 6ter Express Classification de Nice Classification de Vienne Base de données mondiale sur les dessins et modèles Bulletin des dessins et modèles internationaux Base de données Hague Express Classification de Locarno Base de données Lisbon Express Base de données mondiale sur les marques relative aux indications géographiques Base de données PLUTO sur les variétés végétales Base de données GENIE Traités administrés par l’OMPI WIPO Lex – lois, traités et jugements en matière de propriété intellectuelle Normes de l’OMPI Statistiques de propriété intellectuelle WIPO Pearl (Terminologie) Publications de l’OMPI Profils nationaux Centre de connaissances de l’OMPI Série de rapports de l’OMPI consacrés aux tendances technologiques Indice mondial de l’innovation Rapport sur la propriété intellectuelle dans le monde PCT – Le système international des brevets ePCT Budapest – Le système international de dépôt des micro-organismes Madrid – Le système international des marques eMadrid Article 6ter (armoiries, drapeaux, emblèmes nationaux) La Haye – Le système international des dessins et modèles industriels eHague Lisbonne – Le système d’enregistrement international des indications géographiques eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange Médiation Arbitrage Procédure d’expertise Litiges relatifs aux noms de domaine Accès centralisé aux résultats de la recherche et de l’examen (WIPO CASE) Service d’accès numérique aux documents de priorité (DAS) WIPO Pay Compte courant auprès de l’OMPI Assemblées de l’OMPI Comités permanents Calendrier des réunions WIPO Webcast Documents officiels de l’OMPI Plan d’action de l’OMPI pour le développement Assistance technique Institutions de formation en matière de propriété intellectuelle Mesures d’appui concernant la COVID-19 Stratégies nationales de propriété intellectuelle Assistance en matière d’élaboration des politiques et de formulation de la législation Pôle de coopération Centres d’appui à la technologie et à l’innovation (CATI) Transfert de technologie Programme d’aide aux inventeurs WIPO GREEN Initiative PAT-INFORMED de l’OMPI Consortium pour des livres accessibles L’OMPI pour les créateurs WIPO Translate Speech-to-Text Assistant de classification États membres Observateurs Directeur général Activités par unité administrative Bureaux extérieurs Avis de vacance d’emploi Achats Résultats et budget Rapports financiers Audit et supervision
Arabic English Spanish French Russian Chinese
Lois Traités Jugements Recherche par ressort juridique

Japon

JP010-j

Retour

2009 (Gyo-Hi) 326, Minshu Vol. 65, No. 3

Date of Judgment: April 28, 2011

 

Issuing Authority: Supreme Court

 

Level of the Issuing Authority: Final Instance

 

Type of Procedure: Judicial (Administrative)

 

Subject Matter: Patent (Inventions)

 

Main text of the judgment (decision):

 

1.The final appeal is dismissed.

 

2.The appellant of final appeal shall bear the cost of the final appeal.

 

Reasons:

 

Concerning the reasons for acceptance of final appeal argued by the agents appointed for final appeal, SUDO Noriaki, et al.

1. In this case, the appellee of final appeal, who holds a patent right for Patent No. 3134187 (this patent and patent right shall hereinafter be referred to as the "Patent" and "Patent Right," respectively), seeks revocation of the trial decision issued by the Japan Patent Office (JPO) dismissing the appellee's request for a trial against the examiner's decision to refuse the appellee's application for registration of extension of the duration of the Patent Right.

2. The outline of the facts legally determined by the court of prior instance is as follows.

(1) The Patent (containing 22 claims) was based on the patent application filed on March 6, 1997, for the invention entitled "controlled release composition," and was registered on December 1, 2000.

The invention claimed in the Patent relates to a controlled release composition wherein the core containing medicinal substances is coated by a coating agent that contains a water-insoluble substance, a certain hydrophilic substance, and a certain cross-linked acrylic polymer.

(2) On September 30, 2005, the appellee obtained approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act (hereinafter referred to as the "Disposition") with regard to the pharmaceutical product called "Pacif Capsules 30mg" (hereinafter referred to as the "Pharmaceutical Product"). The Pharmaceutical Product contains morphine hydrochloride as its active ingredient, and has the effect and efficacy of a painkiller for various types of cancers that cause a medium to high level of pain.

(3) Prior to the Disposition, another approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act had been issued to another pharmaceutical product called "OPSO (oral solution) 5mg/10mg" which has the same active ingredient as well as effect and efficacy as those of the Pharmaceutical Product (this approval and pharmaceutical product shall hereinafter be referred to as the "Earlier Disposition" and "Earlier Pharmaceutical Product," respectively). The Earlier Pharmaceutical Product is not included in the technical scope of the patented invention specified by any of the claims for the Patent Right.

(4) On December 16, 2005, the appellee filed an application for registration of extension of the duration of the Patent Right, on the grounds that the appellee had been unable to work the patented invention based on the Patent Right during a certain period of time due to the necessity to obtain the Disposition, but the JPO examiner issued a decision to refuse this application. Dissatisfied with this decision, the appellee filed a request for a trial against the examiner's decision of refusal.

(5) On October 21, 2008, the JPO issued a trial decision dismissing the appellee's request for a trial, holding that since the Earlier Disposition had been issued, prior to the Disposition, with regard to the Earlier Pharmaceutical Disposition which has the same active ingredient as well as effect and efficacy as those of the Pharmaceutical Product, it is not found that it was necessary to obtain the Disposition for the working of the patented invention based on the Patent Right (this trial decision by the JPO shall hereinafter be referred to as the "JPO Decision").

3. Even in the case where, prior to the approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act, which gave rise to the necessity to file an application for registration of extension of the duration of a patent right (this approval shall hereinafter be referred to as the "later disposition"), another approval for manufacturing and sale under said paragraph (hereinafter referred to as the "earlier disposition") had been issued with regard to the pharmaceutical product which has the same active ingredient as well as effect and efficacy as those of the pharmaceutical product covered by the later disposition (the pharmaceutical product covered by the earlier disposition and that covered by the later disposition shall hereinafter be referred to as the "earlier pharmaceutical product" and "later pharmaceutical product," respectively), if the earlier pharmaceutical product is not included in the technical scope of the patented invention specified by any of the claims for the patent right pertaining to the application for registration of extension, it is unreasonable to deny that it was necessary to obtain the later disposition for the working of the patented invention based on said patent right, on the grounds of the existence of the earlier disposition. The purpose of the system of extension of the duration of a patent right is to reclaim the period of time during which the patentee has been unable to work the patented invention due to the necessity to obtain the disposition designated by Cabinet Order as set forth in Article 67, paragraph (2) of the Patent Act. Just because the earlier disposition had been issued with regard to the earlier pharmaceutical product which has the same active ingredient as well as effect and efficacy as those of the later pharmaceutical product, inasmuch as the earlier pharmaceutical product is not included in the technical scope of the patented invention specified by any of the claims for the patent right pertaining to the application for registration of extension, the existence of the earlier disposition does not mean that the patentee must have been able to work the patented invention based on the patent right pertaining to the application for registration of extension where the later pharmaceutical product constitutes the working of said patented invention, nor does it meant that the patentee must have been able to work the patented invention specified by any of the claims for said patent right. If the earlier pharmaceutical product is not included in the technical scope of the patented invention specified by any of the claims for the patent right pertaining to the application for registration of extension, this conclusion is not affected irrespective of how the scope of the effect of the patent right (Article 68-2 of the Patent Act) is defined in the case where the duration could have been extended because of the existence of the earlier disposition.

Since the Earlier Pharmaceutical Product is not included in the technical scope of the patented invention specified by any of the claims for the Patent Right, it is unreasonable to deny, in this case, that it was necessary to obtain the Disposition for the working of the patented invention, on the grounds of the existence of the Earlier Disposition.

4. For the reasons stated above, the ruling by the court of prior instance can be affirmed as justifiable in that the court found the JPO Decision to be illegal, holding that the existence of the Earlier Disposition cannot be the grounds for denying that it was necessary to obtain approval for manufacturing and sale under Article 14, paragraph (1) of the Pharmaceutical Affairs Act for the working of the patented invention based on the Patent Right. We cannot accept the arguments for the final appeal.

Therefore, the judgment has been rendered in the form of the main text by the unanimous consent of the Justices.

(This translation is provisional and subject to revision.)